GlassScriptPhysician profile
Francisco Melendez Quinones
NPI 1659389187
$5,221.57
in general payments reported to CMS, 2019-2025
9 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,831 · 2020: $366 · 2021: $298 · 2022: $248 · 2023: $78.64 · 2024: $259 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,558.57 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,259.01 | 2019-2022 | |
| Boston Scientific Corporation | $468.81 | 2020-2024 | Watchman Flx |
| Abbott Laboratories | $370.58 | 2021-2025 | Portico, Aveir |
| Janssen Pharmaceuticals, INC | $202.79 | 2019-2020 | |
| Amgen INC. | $188.11 | 2019-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2021 | |
| Chiesi USA, INC. | $33.93 | 2020-2021 | |
| Medtronic, INC. | $14.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Melendez Quinones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.